Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Drops By 86.2%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 400 shares, a drop of 86.2% from the January 15th total of 2,900 shares. Based on an average trading volume of 14,500 shares, the short-interest ratio is presently 0.0 days.

Scinai Immunotherapeutics Price Performance

SCNI remained flat at $3.32 during trading on Wednesday. The company had a trading volume of 4,012 shares, compared to its average volume of 18,425. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.16 and a current ratio of 1.16. Scinai Immunotherapeutics has a 52-week low of $2.23 and a 52-week high of $8.92. The firm’s fifty day moving average price is $3.47 and its 200-day moving average price is $3.57. The stock has a market cap of $2.82 million, a PE ratio of -0.01 and a beta of 2.37.

Scinai Immunotherapeutics (NASDAQ:SCNI) last announced its quarterly earnings results on Friday, November 22nd. The company reported $8.40 earnings per share (EPS) for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.